All-Atom Receptor-Aware Deep Learning Model Advances De Novo Peptide Binder Design
- Researchers developed REAPS, a geometric graph neural network for designing peptide binder sequences that models the target receptor as a fully observable, all-atom structural context, rather than relying on backbone geometry alone as typical inverse-folding methods do.
- In head-to-head evaluations against the widely used inverse-folding model ProteinMPNN, REAPS showed improved sequence recovery, structural fidelity, and interface-level biophysical properties for both linear and macrocyclic peptide binders.
- The team paired REAPS with structural hallucination in a closed-loop de novo design pipeline to generate novel peptide candidates without requiring a known starting scaffold.
- Candidates produced through this pipeline were synthesized and tested against the neurokinin-3 receptor (NK3R), where they showed experimentally confirmed functional activity.
Sequence recovery and "improved structural fidelity" benchmarks against ProteinMPNN are nice, but what I actually care about is whether the closed-loop hallucination + REAPS pipeline produced binders without a template scaffold — that's the real test, and NK3R hits with confirmed functional activity clear that bar. All-atom receptor context should, in principle, capture side-chain packing and H-bond networks that backbone-only inverse folding misses, which matters a lot for macrocycle design where conformational preorganization is everything. Before I'd plug this into a campaign: what's the actual hit rate and binding affinity on those synthesized NK3R peptides, not just "functional activity"? And does performance hold on a GPCR-like target outside training distribution, or is this another tool that shines on its own benchmark set and stalls on my target. Worth piloting on a live target before I swap out MPNN wholesale.